20 (AIDX) Operating Leases (2024 - 2026)
20 (AIDX) reported Operating Leases of $429122.0 for Q1 2026, down 12.2% quarter-over-quarter from $488725.0 in Q4 2025.
20 (AIDX) Operating Leases (2024 - 2026) Analysis & Trends
20 has reported Operating Leases for 3 years, with the latest figure at $429122.0 in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $429122.0; the trailing twelve-month figure through Mar 2026 stood at $429122.0 (changed N/A YoY), and the FY2025 full-year result was $488725.0, down 27.47% from the prior year.
- Operating Leases for Q1 2026 stood at $429122.0, down from $488725.0 in the prior quarter.
- The five-year high for Operating Leases was $673848.0 in Q4 2024, with the low at $429122.0 in Q1 2026.
- Historically, Operating Leases has averaged $530565.0 across 3 years, with a median of $488725.0 in 2025.
- The largest YoY upside for Operating Leases was 27.47% in 2025 against a maximum downside of 27.47% in 2025.
- 20's Operating Leases stood at $673848.0 in 2024, then retreated by 27.47% to $488725.0 in 2025, then declined by 12.2% to $429122.0 in 2026.
- The last three Operating Leases figures came in at $429122.0 (Q1 2026), $488725.0 (Q4 2025), and $673848.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | 20 | - | - | 62,884.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 429,122.00 |
| Dec 31, 2025 | 488,725.00 |
| Dec 31, 2024 | 673,848.00 |